Analysts Set Applied Therapeutics, Inc. (NASDAQ:APLT) PT at $6.10

Applied Therapeutics, Inc. (NASDAQ:APLT) has been given an average rating of “Moderate Buy” by the seven brokerages that are presently covering the company, MarketBeat.com reports. Three analysts have rated the stock with a hold rating and four have given a buy rating to the company. The average 12 month price objective among brokers that have updated their coverage on the stock in the last year is $6.10.

Several analysts have recently weighed in on the stock. William Blair lowered shares of Applied Therapeutics from an “outperform” rating to a “market perform” rating in a research note on Monday, December 23rd. Leerink Partners upped their price objective on shares of Applied Therapeutics from $11.00 to $14.00 and gave the company an “outperform” rating in a report on Thursday, September 19th. UBS Group restated a “neutral” rating and issued a $2.00 target price (down from $13.00) on shares of Applied Therapeutics in a research note on Monday, December 2nd. Robert W. Baird decreased their target price on Applied Therapeutics from $14.00 to $5.00 and set an “outperform” rating for the company in a research report on Friday, November 29th. Finally, Citigroup cut their price target on Applied Therapeutics from $13.00 to $8.00 and set a “buy” rating on the stock in a report on Friday, November 29th.

Institutional Trading of Applied Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the stock. Barclays PLC boosted its position in shares of Applied Therapeutics by 186.1% during the third quarter. Barclays PLC now owns 200,012 shares of the company’s stock valued at $1,702,000 after buying an additional 130,102 shares during the last quarter. Y Intercept Hong Kong Ltd bought a new stake in shares of Applied Therapeutics in the 3rd quarter worth $149,000. XTX Topco Ltd bought a new stake in shares of Applied Therapeutics in the 3rd quarter worth $531,000. Wellington Management Group LLP bought a new position in shares of Applied Therapeutics during the third quarter valued at about $1,717,000. Finally, State Street Corp lifted its position in shares of Applied Therapeutics by 123.1% during the third quarter. State Street Corp now owns 3,694,607 shares of the company’s stock valued at $31,404,000 after purchasing an additional 2,038,724 shares in the last quarter. 98.31% of the stock is owned by hedge funds and other institutional investors.

Applied Therapeutics Stock Performance

Shares of APLT stock opened at $0.81 on Friday. Applied Therapeutics has a fifty-two week low of $0.77 and a fifty-two week high of $10.62. The stock has a 50 day simple moving average of $5.66 and a two-hundred day simple moving average of $5.97. The company has a market cap of $94.25 million, a P/E ratio of -0.50 and a beta of 1.76.

Applied Therapeutics Company Profile

Applied Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need in the United States. The company's lead product candidate is AT-007 (also called govorestat) that has completed phase 3 for the treatment of galactosemia in healthy volunteers and adults, in pediatric clinical study for the treatment of galactosemia in kids, for treating enzyme sorbitol dehydrogenase, and for the treatment of phosphomannomutase enzyme-CDG.